Literature DB >> 17320628

Transient postictal MRI changes in patients with brain tumors may mimic disease progression.

Michael A Finn1, Deborah T Blumenthal, Karen L Salzman, Randy L Jensen.   

Abstract

BACKGROUND: Transient postictal imaging abnormalities in patients with non-tumor-related seizures are well documented and include fluid-attenuated inversion recovery/T2 hyperintensity and parenchymal and meningeal contrast enhancement. In contrast, transient postictal imaging abnormalities in patients with tumor-related seizures have been poorly described. Fifty percent of patients with brain tumors have a seizure during the course of their illness and are often imaged after a seizure or after a change in seizure character or frequency. Interval changes on repeat imaging can mimic disease progression or other pathologic processes.
METHODS: We describe 3 patients with brain tumors and transient postictal MRI changes that mimicked disease progression and infection.
RESULTS: Our patients demonstrated fluid-attenuated inversion recovery/T2 hyperintensity and gadolinium enhancement on MRI studies performed shortly after ictal events. These changes were suspicious for tumor progression in 2 cases and for recurrent infection in the third. Control of seizure activity resulted in resolution of these changes on scans obtained 10 to 21 days later.
CONCLUSIONS: Imaging shortly after an ictal event can potentially mislead the clinician to interpret changes as tumor or pathologic progression. Unnecessary intervention in these patients with new and suspicious imaging findings should be avoided. We recommend repeat imaging be performed in patients with brain tumors and seizures several weeks after seizure control if clinically feasible. Further research is needed to delineate the time course of seizure-induced MRI changes.

Entities:  

Mesh:

Year:  2006        PMID: 17320628     DOI: 10.1016/j.surneu.2006.04.015

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  23 in total

1.  Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria.

Authors:  Alexander Radbruch; Kira Lutz; Benedikt Wiestler; Philipp Bäumer; Sabine Heiland; Wolfgang Wick; Martin Bendszus
Journal:  Neuro Oncol       Date:  2011-12-06       Impact factor: 12.300

Review 2.  The postictal state: effects of age and underlying brain dysfunction.

Authors:  William H Theodore
Journal:  Epilepsy Behav       Date:  2010-08-17       Impact factor: 2.937

3.  Serum concentrations of glial fibrillary acidic protein (GFAP) do not indicate tumor recurrence in patients with glioblastoma.

Authors:  Julia-Mareen Vietheer; Johannes Rieger; Marlies Wagner; Christian Senft; Julia Tichy; Christian Foerch
Journal:  J Neurooncol       Date:  2017-07-17       Impact factor: 4.130

4.  MRI and thallium-201 SPECT in the prediction of survival in glioma.

Authors:  Maaike J Vos; Johannes Berkhof; Otto S Hoekstra; Ingeborg Bosma; Eefje M Sizoo; Jan J Heimans; Jaap C Reijneveld; Esther Sanchez; Frank J Lagerwaard; Jan Buter; David P Noske; Tjeerd J Postma
Journal:  Neuroradiology       Date:  2011-07-14       Impact factor: 2.804

5.  Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).

Authors:  Patrick Y Wen; Timothy F Cloughesy; Benjamin M Ellingson; David A Reardon; Howard A Fine; Lauren Abrey; Karla Ballman; Martin Bendszuz; Jan Buckner; Susan M Chang; Michael D Prados; Whitney B Pope; Alma Gregory Sorensen; Martin van den Bent; Wai-Kwan Alfred Yung
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

6.  Peri-ictal pseudoprogression in patients with brain tumor.

Authors:  Sylvain Rheims; Damien Ricard; Martin van den Bent; Luc Taillandier; Véronique Bourg; Virginie Désestret; Stéphanie Cartalat-Carel; Marc Hermier; Annick Monjour; Jean-Yves Delattre; Marc Sanson; Jérôme Honnorat; François Ducray
Journal:  Neuro Oncol       Date:  2011-07       Impact factor: 12.300

7.  Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value.

Authors:  R-E Yoo; S H Choi; T M Kim; S-H Lee; C-K Park; S-H Park; I H Kim; T J Yun; J-H Kim; C H Sohn
Journal:  AJNR Am J Neuroradiol       Date:  2015-08-20       Impact factor: 3.825

8.  Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.

Authors:  Fatima Tensaouti; Jonathan Khalifa; Amélie Lusque; Benjamin Plas; Jean Albert Lotterie; Isabelle Berry; Anne Laprie; Elizabeth Cohen-Jonathan Moyal; Vincent Lubrano
Journal:  Neuroradiology       Date:  2017-08-25       Impact factor: 2.804

9.  Seizures during the management of high-grade gliomas: clinical relevance to disease progression.

Authors:  Young-Hoon Kim; Chul-Kee Park; Tae Min Kim; Seung Hong Choi; Yu Jung Kim; Byung Se Choi; Jung Ho Han; Se-Hoon Lee; Chae-Yong Kim; In Ah Kim; Dae Seog Heo; Il Han Kim; Dong Gyu Kim; Hee-Won Jung
Journal:  J Neurooncol       Date:  2013-03-04       Impact factor: 4.130

10.  Prognostic significance of imaging contrast enhancement for WHO grade II gliomas.

Authors:  Johan Pallud; Laurent Capelle; Luc Taillandier; Denys Fontaine; Emmanuel Mandonnet; Rémy Guillevin; Luc Bauchet; Philippe Peruzzi; Florence Laigle-Donadey; Michèle Kujas; Jacques Guyotat; Marie-Hélène Baron; Karima Mokhtari; Hugues Duffau
Journal:  Neuro Oncol       Date:  2008-08-12       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.